AK102 + Placebo + Statins and/or Ezetimibe
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Heterozygous Familial Hypercholesterolemia
Conditions
Heterozygous Familial Hypercholesterolemia
Trial Timeline
Nov 18, 2019 → Sep 26, 2022
NCT ID
NCT04173793About AK102 + Placebo + Statins and/or Ezetimibe
AK102 + Placebo + Statins and/or Ezetimibe is a phase 2 stage product being developed by Akeso for Heterozygous Familial Hypercholesterolemia. The current trial status is completed. This product is registered under clinical trial identifier NCT04173793. Target conditions include Heterozygous Familial Hypercholesterolemia.
What happened to similar drugs?
1 of 15 similar drugs in Heterozygous Familial Hypercholesterolemia were approved
Approved (1) Terminated (1) Active (14)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04173793 | Phase 2 | Completed |
Competing Products
18 competing products in Heterozygous Familial Hypercholesterolemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AZD0780 + Placebo | AstraZeneca | Phase 3 | 44 |
| Anacetrapib + Placebo for anacetrapib | Merck | Phase 3 | 40 |
| Enlicitide Decanoate + Placebo | Merck | Phase 2/3 | 45 |
| Inclisiran | Novartis | Phase 3 | 44 |
| Inclisiran + Placebo | Novartis | Phase 3 | 40 |
| Fluvastatin | Novartis | Phase 3 | 40 |
| Inclisiran + Placebo | Novartis | Phase 3 | 47 |
| Evolocumab + Placebo | Amgen | Phase 3 | 40 |
| Bococizumab (PF-04950615;RN316) | Pfizer | Phase 3 | 40 |
| Atorvastatin + Atorvastatin | Pfizer | Phase 1 | 29 |
| IBI306 + placebo | Innovent Biologics | Phase 3 | 40 |
| Lumacaftor Plus Ivacaftor Combination + Ivacaftor | Vertex Pharmaceuticals | Phase 3 | 40 |
| LMT (atorvastatin, simvastatin, or rosuvastatin) + alirocumab + Placebo | Sanofi | Phase 3 | 40 |
| Placebo + Alirocumab | Sanofi | Phase 3 | 40 |
| Praluent | Sanofi | Approved | 35 |
| lerodalcibep | Medpace | Phase 3 | 37 |
| mipomersen sodium + placebo | Ionis Pharmaceuticals | Phase 3 | 37 |
| MGL-3196 (resmetirom) + Placebo | Madrigal Pharmaceuticals | Phase 2 | 32 |